HomeCompareRCOR vs PM

RCOR vs PM: Dividend Comparison 2026

RCOR yields 62.50% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RCOR wins by $686.4K in total portfolio value
10 years
RCOR
RCOR
● Live price
62.50%
Share price
$3.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$735.9K
Annual income
$177,443.13
Full RCOR calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — RCOR vs PM

📍 RCOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRCORPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RCOR + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RCOR pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RCOR
Annual income on $10K today (after 15% tax)
$5,312.50/yr
After 10yr DRIP, annual income (after tax)
$150,826.66/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, RCOR beats the other by $148,708.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RCOR + PM for your $10,000?

RCOR: 50%PM: 50%
100% PM50/50100% RCOR
Portfolio after 10yr
$392.8K
Annual income
$89,967.57/yr
Blended yield
22.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

RCOR
Analyst Ratings
2
Buy
Consensus: Buy
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RCOR buys
0
PM buys
0
No recent congressional trades found for RCOR or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRCORPM
Forward yield62.50%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$735.9K$49.6K
Annual income after 10y$177,443.13$2,492.02
Total dividends collected$614.9K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: RCOR vs PM ($10,000, DRIP)

YearRCOR PortfolioRCOR Income/yrPM PortfolioPM Income/yrGap
1← crossover$16,950$6,250.00$11,648$408.29+$5.3KRCOR
2$28,037$9,900.70$13,589$495.90+$14.4KRCOR
3$45,305$15,305.49$15,877$603.21+$29.4KRCOR
4$71,591$23,114.13$18,580$734.88+$53.0KRCOR
5$110,737$34,135.17$21,781$896.75+$89.0KRCOR
6$167,835$49,346.36$25,578$1,096.12+$142.3KRCOR
7$249,481$69,897.34$30,092$1,342.17+$219.4KRCOR
8$364,047$97,102.68$35,470$1,646.46+$328.6KRCOR
9$521,955$132,424.34$41,892$2,023.58+$480.1KRCOR
10$735,935$177,443.13$49,578$2,492.02+$686.4KRCOR

RCOR vs PM: Complete Analysis 2026

RCORStock

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

Full RCOR Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this RCOR vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RCOR vs SCHDRCOR vs JEPIRCOR vs ORCOR vs KORCOR vs MAINRCOR vs MORCOR vs BTIRCOR vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.